Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

Patrice Forget; Martine Berlière; Aline van Maanen; Francois P. Duhoux; Jean-Pascal Machiels; Pierre G. Coulie; Gauthier Bouche; Marc De Kock; Ketorolac in Breast Cancer trial (KBCtrial) group

doi:10.1016/j.mehy.2013.07.033

Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

Patrice Forget^* (Corresponding Author)
, Martine Berlière
, Aline van Maanen
, Francois P. Duhoux
, Jean-Pascal Machiels
, Pierre G. Coulie
, Gauthier Bouche
, Marc De Kock
, Ketorolac in Breast Cancer trial (KBCtrial) group

^*Corresponding author for this work

Applied Health Sciences

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).

Original language	English
Pages (from-to)	707-712
Number of pages	6
Journal	Medical Hypotheses
Volume	81
Issue number	4
Early online date	9 Aug 2013
DOIs	https://doi.org/10.1016/j.mehy.2013.07.033
Publication status	Published - Oct 2013

Bibliographical note

Financial support
This work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Université catholique de Louvain, St-Luc Hospital.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mehy.2013.07.033Licence: Unspecified

Cite this

Forget, P., Berlière, M., van Maanen, A., Duhoux, F. P., Machiels, J.-P., Coulie, P. G., Bouche, G., De Kock, M., & Ketorolac in Breast Cancer trial (KBCtrial) group (2013). Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Medical Hypotheses, 81(4), 707-712. https://doi.org/10.1016/j.mehy.2013.07.033

Forget, P, Berlière, M, van Maanen, A, Duhoux, FP, Machiels, J-P, Coulie, PG, Bouche, G, De Kock, M & Ketorolac in Breast Cancer trial (KBCtrial) group 2013, 'Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial', Medical Hypotheses, vol. 81, no. 4, pp. 707-712. https://doi.org/10.1016/j.mehy.2013.07.033

@article{2ed18b53362540d2ad19ab335dc1b270,

title = "Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial",

abstract = "Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).",

author = "Patrice Forget and Martine Berli{\`e}re and \{van Maanen\}, Aline and Duhoux, \{Francois P.\} and Jean-Pascal Machiels and Coulie, \{Pierre G.\} and Gauthier Bouche and \{De Kock\}, Marc and \{Ketorolac in Breast Cancer trial (KBCtrial) group\}",

note = "Financial support This work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Universit{\'e} catholique de Louvain, St-Luc Hospital.",

year = "2013",

month = oct,

doi = "10.1016/j.mehy.2013.07.033",

language = "English",

volume = "81",

pages = "707--712",

journal = "Medical Hypotheses",

issn = "0306-9877",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Perioperative ketorolac in high risk breast cancer patients

T2 - Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

AU - Forget, Patrice

AU - Berlière, Martine

AU - van Maanen, Aline

AU - Duhoux, Francois P.

AU - Machiels, Jean-Pascal

AU - Coulie, Pierre G.

AU - Bouche, Gauthier

AU - De Kock, Marc

AU - Ketorolac in Breast Cancer trial (KBCtrial) group

N1 - Financial support This work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Université catholique de Louvain, St-Luc Hospital.

PY - 2013/10

Y1 - 2013/10

N2 - Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).

AB - Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).

UR - https://www.scopus.com/pages/publications/84883765692

U2 - 10.1016/j.mehy.2013.07.033

DO - 10.1016/j.mehy.2013.07.033

M3 - Article

SN - 0306-9877

VL - 81

SP - 707

EP - 712

JO - Medical Hypotheses

JF - Medical Hypotheses

IS - 4

ER -

Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this